

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Health Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that on 2 February 2026, a total of 40,638,000 share options (the “**Option(s)**”) to subscribe for up to a total of 40,638,000 ordinary shares of HK\$0.1 each (the “**Share(s)**”) of the Company, representing approximately 3.03% of the issued share capital of the Company as at the date of this announcement, were granted to 11 eligible participants (the “**Grantee(s)**”) under the share option scheme adopted by the Company on 18 September 2023 (the “**Scheme**”), subject to the acceptance of the Grantees. Details of the Options granted are as follows:

Date of grant	:	2 February 2026 (the “ Date of Grant ”)
Number of the Options granted	:	40,638,000 (each Option shall entitle the holder thereof to subscribe for one Share)
Exercise price of the Options granted	:	HK\$0.66 per Share, which is not less than the highest of (i) HK\$0.61, being the closing price of the Shares as stated in the daily quotations sheet of the Stock Exchange on the Date of Grant; (ii) HK\$0.65, being the average closing price of the Shares as stated in the daily quotations sheets of the Stock Exchange for the five consecutive trading days immediately preceding the Date of Grant; and (iii) HK\$0.1, being the nominal value of the Shares.)

Consideration for the grant of the Options	:	HK\$1.00 to be paid by each Grantee upon acceptance of the Options granted
Exercise period of Options granted	:	The Options vested according to the paragraph below may be exercised by the Grantees at any time until the expiry of 10 years from the Date of Grant.
Vesting period of Options granted	:	All Options granted shall be vested on the date falling the first anniversary of the Date of Grant (i.e. 2 February 2027).
Performance targets	:	There is no performance target attached to the grant of Options. In view that (i) the Grantees are directors or employees of the Group who has been contributing and will contribute directly to the overall business performance and sustainable development of the Group; and (ii) the grant is a recognition for the Grantees' past contributions to the Group and motivation and incentive for future contribution, the remuneration committee of the Company is of the view that the grant of Options to the Grantees without performance targets is market competitive and aligns with the purpose of the Scheme.
Clawback mechanism	:	The Board has the authority to provide that any Option shall be subject to a clawback if the Grantee of an outstanding Option ceases to be an eligible participant by reason of the termination of his or her employment or engagement on the grounds that he or she has been guilty of fraud or dishonesty or persistent or serious misconduct, or appears either to be unable to pay or to have no reasonable prospect of being able to pay his or her debts or has become bankrupt or has made any arrangement or composition with his or her creditors generally, or has been convicted of any criminal offence involving his or her integrity or honesty or on any other ground on which an employer would be entitled to terminate his or her employment summarily.
Financial assistance	:	There have been no arrangements for the Group to provide financial assistance to the Grantees to facilitate the subscription of Shares under the Scheme.

The offer of the Options to each of the Grantees had been approved by the Board.

Among the total of 40,638,000 Options granted, 11,166,000 Options were granted to a director, chief executive or substantial shareholder of the Company, or their respective associates, the details of which are as follows:

Name	Positions/Relationship	Number of Options granted
Ying Rensi (<i>Note</i>)	Executive Director and associate of a substantial shareholder of the Company	1,338,000
Cao Xu	Chairman of the Board and Executive Director	4,914,000
Chung Ho	Executive Director and Chief Executive Officer	4,914,000
		11,166,000

Note: Ms. Ying Rensi is the daughter of Mr. Ying Wei, a non-executive Director and controlling shareholder of the Company.

Pursuant to Rule 17.04(1) of the Listing Rules, the grant of the Options to the above Directors had been approved by the independent non-executive directors of the Company and each of the above Directors had abstained from voting on the resolution approving the grant of the Options in which he or she is the Grantee.

The remaining 29,472,000 Options were granted to employees of the Company who are not a director, chief executive or substantial shareholder of the Company, or any of their respective associates (as defined under the Listing Rules) as at the date of this announcement.

Number of Shares Available for Future Grants

After the above grant of Options, assuming all the Grantees have accepted such grant, the number of Shares available for future grants under the Scheme Mandate Limit and the Service Provider Sublimit of the Scheme is 7,261,476 and 4,789,947 respectively.

By order of the Board
China Health Group Limited
Cao Xu

Chairman of the Board and Executive Director

Hong Kong, 2 February 2026

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Cao Xu (Chairman), Mr. Chung Ho and Ms. Ying Rensi; two non-executive Directors, namely, Mr. Ying Wei, and Mr. Huang Lianhai; and three independent non-executive Directors, namely, Mr. Li Hongyi, Mr. Wu Hui and Mr. Yang Huimin.